Proviral Sequencing Driven Development of Enhanced IPDAv2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials

Accelevir Diagnostics, Llc, Baltimore MD

Investigators

Abstract

The objective of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. The assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and in prospective clinical trials. An additional goal of the program is to develop secondary assays that are not tissue culture-based and discriminate between actively transcribed and latent full-length proviruses. This contract is to develop and validate version 2 of the IPDA for use across major HIV-1 Group M subtypes and recombinants.